Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
The Clinical Efficacy of Immunomodulators in RA Patients
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 400
- Registration Number
- NCT05626348
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 15
- Registration Number
- NCT05605587
- Locations
- 🇨🇭
Unispital Basel, Basel, Switzerland
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
- Conditions
- Acute Graft Versus Host DiseaseHematopoietic and Lymphoid System Neoplasm
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT05443425
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
New Clinical End-points in Patients With Primary Sjögren's Syndrome
- Conditions
- Primary Sjögren's Syndrome (pSS)
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 300
- Registration Number
- NCT05113004
- Locations
- 🇫🇷
Eric Hachulla, Lille, France
🇫🇷Raphaele Seror, Le Kremlin-Bicêtre, Ile De France, France
🇫🇷Jacques Morel, Montpellier, France
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT05014646
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Ashford and St. Peter's Hospitals NHS Trust
- Target Recruit Count
- 178
- Registration Number
- NCT05007678
- Locations
- 🇬🇧
Ashford and St Peters Hospital NHS Foundation Trust, Chertsey, United Kingdom
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Deborah Doroshow
- Target Recruit Count
- 24
- Registration Number
- NCT04997993
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 10
- Registration Number
- NCT04932564
- Locations
- 🇮🇳
Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra, India
Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
- Conditions
- ANCA Associated VasculitisMaintenance Therapy
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 114
- Registration Number
- NCT04737343
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳AnHui provincial hospital, Hefei, Anhui, China
🇨🇳the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
CHronic Nonbacterial Osteomyelitis International Registry
- Conditions
- Chronic Recurrent Multifocal OsteomyelitisChronic Nonbacterial Osteomyelitis
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.